The epidermal growth factor receptor (EGFR)-S442F mutant displays increased affinity for neuregulin-2β and agonist-independent coupling with downstream signalling events

Biochemical Journal

Volumn 396, Issue 1, 2006, Pages 79-88

  Gilmore, Jennifer L ^a   Gallo, Richard M ^a   Riese II, David J ^a,b  

^a PURDUE UNIVERSITY   (United States)

^b Purdue University   (United States)

Author keywords

Affinity; Apoptosis; Constitutive signal transduction; Epidermal growth factor receptor; Neuregulin 2 ; Phosphoinositide 3 kinase

Indexed keywords

CELLS; GENETIC ENGINEERING; GROWTH KINETICS; TUMORS;

AFFINITY; APOPTOSIS; CONSTITUTIVE SIGNAL TRANSDUCTION; EPIDERMAL GROWTH FACTOR RECEPTOR; NEUREGULIN-2Β; PHOSPHOINOSITIDE 3-KINASE;

PROTEINS;

EPIDERMAL GROWTH FACTOR RECEPTOR; LEUCINE; NEU DIFFERENTIATION FACTOR; NEUREGULIN 2 BETA; SERINE; UNCLASSIFIED DRUG; VALINE;

ALLELE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; MOUSE; NONHUMAN; PHENOTYPE; PHOSPHORYLATION; POINT MUTATION; PRIORITY JOURNAL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; AMINO ACID SUBSTITUTION; ANIMALS; APOPTOSIS; BINDING SITES; CELL LINE; CHROMONES; EPIDERMAL GROWTH FACTOR; GENES, ERBB-1; HUMANS; HYDROPHOBICITY; LIGANDS; MICE; MORPHOLINES; MUTATION, MISSENSE; MYELOID CELLS; NEUREGULINS; PHOSPHORYLATION; POINT MUTATION; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 33646814947     PISSN: 02646021     EISSN: None     Source Type: Journal    
DOI: 10.1042/BJ20051687     Document Type: Article

References (35)

1. Yarden, Y. and Sliwkowski, M. X. (2001) Untangling the ErbB signaling network. Nat. Rev. Mol. Cell Biol. 2, 127-137
2. Hynes, N. E. and Lane, H. A. (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 5, 341-354
3. Ekstrand, A. J., Sugawa, N., James, C. D. and Collins, V. P. (1992) Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc. Natl. Acad. Sci. U.S.A. 89, 4309-4313
4. Wikstrand, C. J., Hale, L. P., Batra, S. K., Hill, M. L., Humphrey, P. A., Kurpad, S. N., McLendon, R. E., Moscatello, D., Pegram, C. N. and Reist, C. J. (1995) Monoclonal antibodies against EGFRVIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 55, 3140-3148
5. Sugawa, N., Ekstrand, A. J., James, C. D., and Collins, V. P. (1990) Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc. Natl. Acad. Sci. U.S.A. 87, 8602-8606
6. Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G. et al. (2004) Activating mutations in the epidermal growth factor receptor underling responsiveness of non-small-cell lung cancer to Gefitinib. N. Engl. J. Med. 350, 2129-2139
7. Sordella, R., Bell, D. W., Haber, D. A. and Settleman, J. (2004) Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305, 1163-1167
8. Kobayashi, S., Boggon, T. J., Dayaram, T., Janne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G. and Halmos, B. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786-792
9. Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G. and Varmus, H. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLos Med. 2, 225-235
10. Kwak, E. L., Sordella, R., Bell, D. W., Godin-Heymann, N., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Driscoll, D. R., Fidias, P., Lynch, T. J. et al. (2005) Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl. Acad. Sci. U.S.A. 102, 7665-7670
11. Pinkas-Kramarski, R., Shelly, M., Guarino, B. C., Wang, L. M., Lyass, L., Alroy, I., Alimandi, M., Kuo, A., Moyer, J. D., Lavi, S. et al. (1998) ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network. Mol. Cell. Biol. 18, 6090-6101
12. Hobbs, S. S., Coffing, S. L., Le, A. T. D., Cameron, E. M., Williams, E. E., Andrew, M., Blommel, E. N., Hammer, R. P., Chang, H. and Riese, II, D. J. (2002) Neuregulin isoforms exhibit distinct patterns of ErbB family receptor activation. Oncogene 21, 8442-8452
13. Hobbs, S. S., Cameron, E. M., Hammer, R. P., Le, A. T., Gallo, R. M., Blommel, E. N., Coffing, S. L., Chang, H. and Riese, II, D. J. (2004) Five carboxyl-terminal residues of neuregulin2 are critical for stimulation of signaling by the ErbB4 receptor tyrosine kinase. Oncogene 23, 883-893
14. 45 of NRG2β is critical for the affinity of NRG2β for ErbB4 and for potent stimulation of ErbB4 signaling by NRG2β. Growth Factors 23, 273-283
15. Garrett, T. P. J., McKern, N. M., Lou, M., Elleman, T. C., Adams, T. E., Lovercz, G. O., Zhu, H.-J., Walker, F., Frenkel, M. J., Hoyne, P. A. et al. (2002) Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor α. Cell 110, 763-773
16. Ogiso, H., Ishitani, R., Nureki, O., Fukal, S., Yamanaka, M., Kim, J.-H., Saito, K., Sakamoto, A., Inoue, M., Shirouzu, M. et al. (2002) Crystal structure of the complex of human epidermal growth factor and receptor extracellular domain. Cell 110, 775-787
17. Luo, C., Xu, L., Zheng, S., Luo, X., Shen, J., Jiang, H., Liu, X. and Zhou, M. (2005) Computational analysis of molecular basis of 1:1 interactions of NRG1β wild-type and variants with ErbB3 and ErbB4. Proteins Struct. Fund. Bioinform. 59, 749-756
18. Riese, II, D. J., van Raaij, T. M., Plowman, G. D., Andrews, G. C. and Stern, D. F. (1995) The cellular response to neuregulins is governed by complex interactions of the erbB receptor family. Mol. Cell. Biol. 15, 5770-5776
19. Williams, E. E., Trout, L. J., Gallo, R. M., Pitfield, S. E., Bryant, I., Penington, D. J. and Riese, II, D. J. (2003) A constitutively active ErbB4 mutant inhibits drug-resistant colony formation by the DU-145 and PC-3 human prostate tumor cell lines. Cancer Lett. 192, 67-74
20. Feroz, K., Williams, E. and Riese, II, D. J. (2002) ErbB2 and ErbB3 do not quantitatively modulate ligand-induced ErbB4 tyrosine phosphorylation. Cell. Signalling 14, 793-798
21. Riese, II, D. J., Kim, E. D., Elenius, K., Buckley, S., Klagsbrun, M., Plowman, G. D. and Stern, D. F. (1996) The epidermal growth factor receptor couples the transforming growth factor-α, neparin-binding epidermal growth factor-like factor, and amphiregulin to Neu, ErbB-3, and ErbB-4. J. Biol. Chem. 271, 20047-20052
22. Riese, II, D. J., Bermingham, Y., van Raaij, T. M., Buckley, S., Plowman, G. D. and Stern, D. F. (1996) Betacellulin activates the epidermal growth factor receptor and erbB-4 and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-β. Oncogene 12, 345-353
23. Ferguson, K. M., Berger, M. B., Mendrola, J. M., Cho, H.-S., Leahy, D. J. and Lemmon, M. A. (2003) EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol. Cell 11, 507-517
24. Riese, II, D. J., Komurasaki, T., Plowman, G. D. and Stern, D. F. (1998) Activation of ErbB4 by the bifunctional epidermal growth factor family hormone epiregulin is regulated by ErbB2. J. Biol. Chem. 273, 11288-11294
25. Ettenberg, S. A., Keane, M. M., Nau, M. M., Frankel, M., Wang, L. M., Pierce, J. H. and Lipkowitz, S. (1999) Cbl-b inhibits epidermal growth factor receptor signaling. Oncogene 18, 1855-1866
26. VanBrocklin, H. F., Lim, J. K., Coffing, S. L., Horn, D. L., Negash, K., Ono, M. Y., Gilmore, J. L., Bryant, I. and Riese, II, D. J. (2005) Anilinodialkoxyquinazolines: screening epidermal growth factor receptor tyrosine kinase inhibitors for potential tumor imaging probes. J. Med. Chem. 48, 7445-7456
27. Songyang, Z., Baltimore, D., Cantley, L. C., Kaplan, D. R. and Franke, T. F. (1997) Interleukin 3-dependent survival by the Akt protein kinase. Proc. Natl. Acad. Sci. U.S.A. 94, 11345-11350
28. Moriai, T., Kobrin, M. S., Hope, C., Speck, L. and Korc, M. (1994) A variant epidermal growth factor receptor exhibits altered type α transforming growth factor α binding and transmembrane signaling. Proc. Natl. Acad. Sci. U.S.A. 91, 10217-10221
29. Zhang, W., Park, D. J., Lu, B., Yang, D. Y., Gordon, M., Groshen, S., Yun, J., Press, O. A., Vallbohmer, D., Rhodes, K. et al. (2005) Epidermal growth factor receptor gene polymorphisms predict pelvic recurrence in patients with rectal cancer treated with chemoradiation. Clin. Cancer Res. 11, 600-605
30. Burke, C. L. and Stern, D. F. (1998) Activation of Neu (ErbB2) mediated by disulfide bond-induced dimerization reveals a receptor tyrosine kinase dimer interface. Mol. Cell. Biol. 18, 5371-5379
31. Sweeney, C., Lai, C., Riese, II, D. J., Diamonti, A. J., Cantley, L. C. and Carraway, III, K. L. (2000) Ligand discrimination in signaling through an ErbB4 receptor homodimer. J. Biol. Chem. 275, 19803-19807
32. Sweeney, C. and Carraway, III, K. L. (2000) Ligand discrimination by ErbB receptors: differential signaling through differential phosphorylation site usage. Oncogene 19, 5568-5573
33. Amin, D. N., Perkins, A. S. and Stern, D. F. (2004) Gene expression profiling of ErbB receptor and ligand-dependent transcription. Oncogene 23, 1428-1438
34. Saito, T., Okada, S., Ohshima, K., Yamada, E., Sato, M., Uehara, Y., Shimizu, H., Pessin, J. and Mori, M. (2004) Differential activation of epidermal growth factor (EGF) receptor downstream signaling pathways by betacellulin and EGF. Endocrinology 145, 4232-4243
35. Chung, E., Graves-Deal, R., Franklin, J. L. and Coffey, R. J. (2005) Differential effects of amphiregulin and TGF-α on the morphology of MDCK cells. Exp. Cell Res. 309, 149-160